Community Collaboration to Advance Racial/Ethnic Equity in CRC Screening
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 5,127
- 试验地点
- 6
- 主要终点
- CRC Screening Completion Rates
研究概览
简要总结
The goal of this pragmatic randomized clinical trial is to compare two colorectal (CRC) screening outreach approaches (FIT and Cologuard) in community health centers (CHC) in patients overdue for CRC screening. The main questions the project aims to answer are: What screening test has a higher completion rate? What screening test is more feasible and acceptable in a CHC setting? Patients will be sent a CRC screening test in the mail and will be asked to complete it at home and mail it back. Researchers will compare the completion rates for each screening test and will also look at the overall completion rate of both tests.
详细描述
This is a 3-year pragmatic trial with four levels of intervention, including system-, provider-, patient-, and community-level components at each of the CARES clinical sites. Health system components will include the development and implementation of a CRC screening registry and tracking database to systematically and actively track patients overdue for screening, screening test completion, and abnormal screening results. Data systems will be coupled with process re-design to improve clinical workflow for screening outreach. Providers will receive educational support through a training session about the importance of CRC screening, screening test options, population management, and an instructional on how to complete a Cologuard kit (Cologuard arm only) or a FIT kit (FIT arm only). Patient components of the intervention vary by study arm. In sites randomized to Cologuard, patients will receive a mailed Cologuard kit and the Exact Sciences patient support program. Patients in clinics randomized to FIT will receive a mailed FIT kit with systematic reminders. Patients who test positive will be offered patient navigation to assist with completing a diagnostic colonoscopy.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 45 Years 至 75 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Has had a visit at a participating community clinic within the last two years.
- •Patient's preferred language is English or Spanish
排除标准
- •Exclusion Criteria:
- •Has Ulcerative Colitis or Crohn's disease documented in the problem list. (Codes below).
- •Has colorectal cancer documented in the problem list. (Codes below).
- •Has had a FIT in the past 1 year
- •Has had a colonoscopy in the past 10 years
- •ICD-10 codes for exclusion criteria:
- •Ulcerative colitis:
- •Crohn's disease:
- •Colorectal cancer
- •C18 (malignant neoplasm of colon)
- •C18.0 (malignant neoplasm of cecum)
- •C18.1 (malignant neoplasm of appendix)
- •C18.2 (malignant neoplasm of ascending colon)
- •C18.3 (malignant neoplasm of hepatic flexure)
- •C18.4 (malignant neoplasm of transverse colon)
- •C18.5 (malignant neoplasm of splenic flexure)
- •C18.6 (malignant neoplasm of descending colon)
- •C18.7 (malignant neoplasm of sigmoid colon)
- •C18.8 (malignant neoplasm of overlapping sites of colon)
- •C18.9 (malignant neoplasm of colon, unspecified)
- •C19 (malignant neoplasm of rectosigmoid junction)
- •C20 (malignant neoplasm of rectum)
- •C21.8 (malignant neoplasm of overlapping sites of rectum, anus and anal canal)
- •C26.0 (malignant neoplasm of intestinal tract, part unspecified)
- •C78.5 (secondary malignant neoplasm of large intestine and rectum)
- •C78.6 (secondary malignant neoplasm of retroperitoneum and peritoneum)
- •D37.4 (neoplasm of uncertain behavior of colon)
- •D37.5 (neoplasm of uncertain behavior of rectum)
结局指标
主要结局
CRC Screening Completion Rates
时间窗: 3 months
completion rate of the stool-based screening test (FIT or Cologuard)
CRC Screening Completion Rates
时间窗: 3 months
completion rate of the stool-based screening test (FIT or Cologuard)
次要结局
- Diagnostic Colonoscopy Completion Rates(6 months)
- CRC Screening Completion Rates(6 months)
研究者
Jennifer S Haas, MD
Principal Investigator
Massachusetts General Hospital
